Search

The magnetic chitosan/sludge biochar composite adsorbent was prepared using chitosan, Fe3O4, and sludge biochar as raw materials. The composite adsorbent was able to achieve rapid solid–liquid separation under an applied magnetic field. The morphology and microstructure of the composite adsorbent were characterized by FTIR, XRD, SEM, VSM, and BET analysis. The adsorption performance of the composite adsorbent on Cu2+ was investigated through static adsorption experiments, and the effects of adsorbent dosage, initial concentration of Cu2+, initial pH of the solution, and adsorption temperature on the adsorption efficiency of Cu2+ were discussed. The results showed that chitosan and Fe3O4 were successfully loaded on sludge biochar. When the initial concentration of Cu2+ was 30 mg/L, the dosage of the magnetic chitosan/sludge biochar composite material was 0.05 g, the adsorption time was 180 min, pH was 5, and the temperature was room temperature, the maximum removal rate of Cu2+ reached 99.77%, and the maximum adsorption capacity was 55.16 mg/g. The adsorption kinetics and adsorption isotherm data fitted well with the pseudo-second-order kinetic model and Langmuir adsorption isotherm model, indicating that the adsorption process was chemisorption with monolayer coverage. [ABSTRACT FROM AUTHOR]

In the nervous system, excessive activation of NMDA receptors causes neuronal injury. Although activation of NMDARs has been proposed to contribute to the progress of diabetes, little is known about the effect of excessive long-term activation of NMDARs on β-cells, especially under the challenge of hyperglycemia. Here we thoroughly investigated whether endogenous glutamate aggravated β-cell dysfunction under chronic exposure to high-glucose via activation of NMDARs. The glutamate level was increased in plasma of diabetic mice or patients and in the supernatant of β-cell lines after treatment with high-glucose for 72 h. Decomposing the released glutamate improved GSIS of β-cells under chronic high-glucose exposure. Long-term treatment of β-cells with NMDA inhibited cell viability and decreased GSIS. These effects were eliminated by GluN1 knockout. The NMDAR antagonist MK-801 or GluN1 knockout prevented high-glucose-induced dysfunction in β-cells. MK-801 also decreased the expression of pro-inflammatory cytokines, and inhibited I-κB degradation, ROS generation and NLRP3 inflammasome expression in β-cells exposed to high-glucose. Furthermore, another NMDAR antagonist, Memantine, improved β-cells function in diabetic mice. Taken together, these findings indicate that an increase of glutamate may contribute to the development of diabetes through excessive activation of NMDARs in β-cells, accelerating β-cells dysfunction and apoptosis induced by hyperglycemia. [ABSTRACT FROM AUTHOR]